deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03190278

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMELI-01)

Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Cellectis S.A.

Conditions Relapsed/Refractory Acute Myeloid Leukemia
Interventions UCART123v1.2
Updated 19 times since 2017 Last updated: Aug 4, 2025 Started: Jun 19, 2017 Primary completion: Dec 24, 2024 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Relapsed/Refractory Acute Myeloid Leukemia and is currently ongoing. Cellectis S.A. leads this study, which shows 19 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Jan 2018 · 3 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Jun 2020 · 5 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Jul 2022 · 9 months · monthly snapshot~Jul 2022 – ~Mar 2024 · 20 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2022 — Mar 2024 [monthly]

    Recruiting PHASE1

▶ Show 14 earlier versions

  1. Oct 2021 — Jul 2022 [monthly]

    Recruiting PHASE1

  2. Jun 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  3. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE1

  4. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  6. Jun 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Jan 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  8. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  9. Jan 2019 — Jun 2019 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  11. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE1

    Status: Suspended → Recruiting

  13. Oct 2017 — Jan 2018 [monthly]

    Suspended PHASE1

    Status: Recruiting → Suspended

  14. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cellectis S.A.
Data source: Cellectis S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations